However, since our main findings from the murine Cebpap30/p30/CebpaΔ/p30 models are also observed in human CEBPADM AML (including upregulation of CEBPA and GATA2 in leukemic GMPs compared to normal GMPs, as well as rebalancing of GATA2 expression and worsened outcome by the acquisition of TET2 lesions), we believe that our observations indicate that a similar disease-relevant CEBPA-TET2 axis is active in human CEBPADM AML. This evidence concerns the gene CEBPA and acute myeloid leukemia.